glp-1 mlm Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges Scam weight-loss drops marketed to

North America registered dominance in the market by capturing a 60% share in 2025

Anyone seeking fast-acting appetite suppression

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

So too was Thomsen who in 1996 began 'building an organisation devoted to obesity research' (Holst 2024)

Figure 21: Photograph of Professor Joel Habener, credit: Endocrine Society

CONCLUSIONS Recent investigations have elucidated a multifaceted spectrum of adverse effects linked to GLP-1 RAs (Table 1), necessitating meticulous interpretation based on the various methodological designs employed, including RCTs and retrospective analyses